Marshall Wace LLP lessened its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 0.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,085,335 shares of the specialty chemicals company's stock after selling 31,619 shares during the period. Marshall Wace LLP owned about 4.74% of Chemours worth $119,742,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of CC. Strategic Financial Concepts LLC bought a new stake in shares of Chemours in the 4th quarter valued at about $357,000. Entropy Technologies LP purchased a new position in Chemours during the fourth quarter valued at approximately $266,000. Sei Investments Co. raised its stake in Chemours by 779.5% in the fourth quarter. Sei Investments Co. now owns 174,555 shares of the specialty chemicals company's stock worth $2,950,000 after buying an additional 154,709 shares in the last quarter. Twelve Points Wealth Management LLC lifted its holdings in Chemours by 42.8% during the fourth quarter. Twelve Points Wealth Management LLC now owns 78,325 shares of the specialty chemicals company's stock worth $1,324,000 after buying an additional 23,490 shares during the period. Finally, Geode Capital Management LLC boosted its position in Chemours by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company's stock valued at $50,646,000 after acquiring an additional 28,803 shares in the last quarter. Institutional investors own 76.26% of the company's stock.
Analyst Ratings Changes
CC has been the subject of a number of analyst reports. BMO Capital Markets decreased their price objective on Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research note on Wednesday, February 19th. The Goldman Sachs Group lowered their price target on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. Truist Financial reduced their price objective on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Morgan Stanley lowered their target price on shares of Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, Barclays reduced their price target on Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 1st. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Chemours has a consensus rating of "Moderate Buy" and an average price target of $21.56.
View Our Latest Analysis on CC
Chemours Stock Performance
Shares of CC traded up $0.35 during trading hours on Friday, reaching $11.37. 1,640,388 shares of the company traded hands, compared to its average volume of 1,838,233. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The business has a fifty day moving average price of $13.83 and a 200-day moving average price of $17.31. The Chemours Company has a 12-month low of $9.33 and a 12-month high of $29.21. The stock has a market capitalization of $1.70 billion, a P/E ratio of 19.94 and a beta of 1.84.
Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The business had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.37 billion. Equities analysts anticipate that The Chemours Company will post 2.03 EPS for the current fiscal year.
Chemours Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 8.80%. The ex-dividend date of this dividend was Friday, February 28th. Chemours's payout ratio is 175.44%.
About Chemours
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Articles
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
